Similarly, our current results showed that EB1089 treatment inhibited cell proliferation and restored the antiestrogenic responsiveness of fulvestrant in SK-BR-3 cells, indicating the effectiveness of this combination therapy in inhibiting proliferation in breast cancer cells with the ER-negative/HER2-positive phenotype. This evidence concerns the gene ESR1 and breast carcinoma.